LakeShore Biopharma Co., Ltd. was granted approval for a Phase III clinical trial to explore simplified regimens for its YSJA rabies vaccine on October 25, 2024. This event is significant for the company and is viewed positively by equity investors.
AI Assistant
LAKESHORE BIOPHARMA CO LTD
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.